|
US5969145A
(en)
*
|
1996-08-30 |
1999-10-19 |
Novartis Ag |
Process for the production of epothilones and intermediate products within the process
|
|
CN100344627C
(zh)
*
|
1996-11-18 |
2007-10-24 |
生物技术研究有限公司(Gbf) |
埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用
|
|
US6204388B1
(en)
|
1996-12-03 |
2001-03-20 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
US6867305B2
(en)
|
1996-12-03 |
2005-03-15 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
US6242469B1
(en)
|
1996-12-03 |
2001-06-05 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
|
US20050043376A1
(en)
*
|
1996-12-03 |
2005-02-24 |
Danishefsky Samuel J. |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
|
US6660758B1
(en)
*
|
1996-12-13 |
2003-12-09 |
The Scripps Research Institute |
Epothilone analogs
|
|
US6441186B1
(en)
|
1996-12-13 |
2002-08-27 |
The Scripps Research Institute |
Epothilone analogs
|
|
US6380394B1
(en)
|
1996-12-13 |
2002-04-30 |
The Scripps Research Institute |
Epothilone analogs
|
|
US6605599B1
(en)
|
1997-07-08 |
2003-08-12 |
Bristol-Myers Squibb Company |
Epothilone derivatives
|
|
AU9340998A
(en)
|
1997-08-09 |
1999-03-01 |
Schering Aktiengesellschaft |
New epothilone derivatives, method for producing same and their pharmaceutical use
|
|
US6365749B1
(en)
*
|
1997-12-04 |
2002-04-02 |
Bristol-Myers Squibb Company |
Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
|
|
US6683100B2
(en)
|
1999-01-19 |
2004-01-27 |
Novartis Ag |
Organic compounds
|
|
US6194181B1
(en)
|
1998-02-19 |
2001-02-27 |
Novartis Ag |
Fermentative preparation process for and crystal forms of cytostatics
|
|
US6302838B1
(en)
|
1998-02-25 |
2001-10-16 |
Novartis Ag |
Cancer treatment with epothilones
|
|
FR2775187B1
(fr)
|
1998-02-25 |
2003-02-21 |
Novartis Ag |
Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
|
|
US6498257B1
(en)
*
|
1998-04-21 |
2002-12-24 |
Bristol-Myers Squibb Company |
2,3-olefinic epothilone derivatives
|
|
US6399638B1
(en)
*
|
1998-04-21 |
2002-06-04 |
Bristol-Myers Squibb Company |
12,13-modified epothilone derivatives
|
|
DE19826988A1
(de)
*
|
1998-06-18 |
1999-12-23 |
Biotechnolog Forschung Gmbh |
Epothilon-Nebenkomponenten
|
|
EP1135470A2
(en)
|
1998-11-20 |
2001-09-26 |
Kosan Biosciences, Inc. |
Recombinant methods and materials for producing epothilone and epothilone derivatives
|
|
US6410301B1
(en)
|
1998-11-20 |
2002-06-25 |
Kosan Biosciences, Inc. |
Myxococcus host cells for the production of epothilones
|
|
EP1140944B1
(en)
|
1998-12-22 |
2003-08-27 |
Novartis AG |
Epothilone derivatives and their use as antitumor agents
|
|
US6780620B1
(en)
*
|
1998-12-23 |
2004-08-24 |
Bristol-Myers Squibb Company |
Microbial transformation method for the preparation of an epothilone
|
|
WO2000047584A2
(de)
|
1999-02-11 |
2000-08-17 |
Schering Aktiengesellschaft |
Epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
|
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
|
EP2308833A3
(en)
|
1999-04-15 |
2011-09-28 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
|
AU772750C
(en)
*
|
1999-04-30 |
2005-02-24 |
Schering Aktiengesellschaft |
6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
|
|
EP1229934B1
(en)
|
1999-10-01 |
2014-03-05 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
US6518421B1
(en)
*
|
2000-03-20 |
2003-02-11 |
Bristol-Myers Squibb Company |
Process for the preparation of epothilone analogs
|
|
DE10020899A1
(de)
*
|
2000-04-20 |
2001-10-25 |
Schering Ag |
9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
|
|
US6489314B1
(en)
|
2001-04-03 |
2002-12-03 |
Kosan Biosciences, Inc. |
Epothilone derivatives and methods for making and using the same
|
|
AU2001266583A1
(en)
*
|
2000-05-26 |
2001-12-11 |
Kosan Biosciences, Inc. |
Epothilone derivatives and methods for making and using the same
|
|
UA75365C2
(en)
|
2000-08-16 |
2006-04-17 |
Bristol Myers Squibb Co |
Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
|
|
WO2002030356A2
(en)
|
2000-10-13 |
2002-04-18 |
The University Of Mississipi |
Synthesis of epothilones and relates analogs
|
|
NZ526871A
(en)
|
2001-01-25 |
2006-01-27 |
Bristol Myers Squibb Co |
Pharmaceutical dosage forms of epothilones for oral administration
|
|
CN1489466A
(zh)
*
|
2001-01-25 |
2004-04-14 |
����˹�ж�-����˹˹������˾ |
包含埃博霉素类似物的非肠道制剂
|
|
HRP20030677B1
(hr)
*
|
2001-01-25 |
2011-10-31 |
Bristol-Myers Squibb Company |
Postupci primjene analoga epotilona u liječenju karcinoma
|
|
EP1353668B1
(en)
|
2001-01-25 |
2008-03-19 |
Bristol-Myers Squibb Company |
Processes for the preparation of pharmaceutical preparations containing epothilone analogues for the treatment of cancer
|
|
US6893859B2
(en)
|
2001-02-13 |
2005-05-17 |
Kosan Biosciences, Inc. |
Epothilone derivatives and methods for making and using the same
|
|
MXPA03007394A
(es)
|
2001-02-20 |
2003-12-04 |
Bristol Myers Squibb Co |
Tratamiento de tumores refractarios mediante uso de derivados de epotilona.
|
|
CN1610549A
(zh)
|
2001-02-20 |
2005-04-27 |
布里斯托尔-迈尔斯斯奎布公司 |
用于治疗难治肿瘤的埃坡霉素衍生物
|
|
ATE335746T1
(de)
|
2001-02-27 |
2006-09-15 |
Biotechnolog Forschung Gmbh |
Verfahren zur herstellung von epothilonen
|
|
CA2440555A1
(en)
*
|
2001-03-14 |
2002-09-19 |
Bristol-Myers Squibb Company |
Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
|
|
JP2004532888A
(ja)
|
2001-06-01 |
2004-10-28 |
ブリストル−マイヤーズ スクイブ カンパニー |
エポチロン誘導体
|
|
TWI315982B
(en)
|
2001-07-19 |
2009-10-21 |
Novartis Ag |
Combinations comprising epothilones and pharmaceutical uses thereof
|
|
MXPA04006822A
(es)
|
2002-01-14 |
2004-12-08 |
Novartis Ag |
Combinaciones que comprenden epotilonas y anti-metabolitos.
|
|
EP1340498A1
(en)
*
|
2002-03-01 |
2003-09-03 |
Schering Aktiengesellschaft |
Use of epothilones in the treatment of brain diseases associated with proliferative processes
|
|
WO2003077903A1
(en)
*
|
2002-03-12 |
2003-09-25 |
Bristol-Myers Squibb Company |
C12-cyano epothilone derivatives
|
|
DK1483251T3
(da)
|
2002-03-12 |
2010-04-12 |
Bristol Myers Squibb Co |
C3-cyano-epothilon-derivater
|
|
TW200403994A
(en)
|
2002-04-04 |
2004-03-16 |
Bristol Myers Squibb Co |
Oral administration of EPOTHILONES
|
|
TW200400191A
(en)
*
|
2002-05-15 |
2004-01-01 |
Bristol Myers Squibb Co |
Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
|
|
US7405234B2
(en)
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
|
US7008936B2
(en)
|
2002-06-14 |
2006-03-07 |
Bristol-Myers Squibb Company |
Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
|
|
DE10232094A1
(de)
*
|
2002-07-15 |
2004-02-05 |
GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) |
5-Thiaepothilone und 15-disubstituierte Epothilone
|
|
US7649006B2
(en)
|
2002-08-23 |
2010-01-19 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
US6921769B2
(en)
|
2002-08-23 |
2005-07-26 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
EP2186811A1
(en)
*
|
2002-08-23 |
2010-05-19 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
|
BRPI0314133A8
(pt)
|
2002-09-23 |
2017-09-19 |
Bristol Myers Squibb Co |
Processo para isolamento de epotilona b, métodos para cultivo de microorganismo que produza epotilona a ou b e para purifiação de apotilona
|
|
AU2003264822A1
(en)
*
|
2002-10-11 |
2004-05-04 |
Dana-Farber Cancer Institute Inc |
Epothilone derivatives for the treatment of multiple myeloma
|
|
AU2003302084A1
(en)
|
2002-11-15 |
2004-06-15 |
Bristol-Myers Squibb Company |
Open chain prolyl urea-related modulators of androgen receptor function
|
|
ES2330517T3
(es)
*
|
2002-11-28 |
2009-12-11 |
Wolfgang Richter |
Derivados de tia-epotilona para el tratamiento del cancer.
|
|
CN1723018A
(zh)
*
|
2002-12-09 |
2006-01-18 |
诺瓦提斯公司 |
用于治疗支架狭窄的微管稳定剂
|
|
GB0230024D0
(en)
*
|
2002-12-23 |
2003-01-29 |
Novartis Ag |
Organic compounds
|
|
CN100359014C
(zh)
*
|
2003-01-28 |
2008-01-02 |
北京华昊中天生物技术有限公司 |
一类新型埃坡霉素化合物及其制备方法和用途
|
|
ES2349532T3
(es)
|
2003-02-06 |
2011-01-04 |
Bristol-Myers Squibb Company |
Compuestos basados en tiazolilo útiles como inhibidores de cinasa.
|
|
GB0305928D0
(en)
*
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
|
AU2008200555C1
(en)
*
|
2003-03-14 |
2011-12-15 |
Novartis Ag |
Treatment of proliferative diseases with epothilone derivatives and radiation
|
|
US7371759B2
(en)
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
|
DE10344882A1
(de)
|
2003-09-26 |
2005-04-21 |
Morphochem Ag Komb Chemie |
Neue Makrocyclen zur Behandlung von Krebserkrankungen
|
|
US20050171167A1
(en)
*
|
2003-11-04 |
2005-08-04 |
Haby Thomas A. |
Process and formulation containing epothilones and analogs thereof
|
|
WO2005054429A2
(en)
*
|
2003-11-19 |
2005-06-16 |
The University Of Mississippi |
Synthesis of the c1-c6 keto-acid synthon of the epothilones
|
|
US7420059B2
(en)
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
|
EP1559447A1
(en)
|
2004-01-30 |
2005-08-03 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
|
|
US7820702B2
(en)
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
|
US7378426B2
(en)
|
2004-03-01 |
2008-05-27 |
Bristol-Myers Squibb Company |
Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
|
|
US7625923B2
(en)
|
2004-03-04 |
2009-12-01 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
|
US7696241B2
(en)
|
2004-03-04 |
2010-04-13 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
|
US7459562B2
(en)
|
2004-04-23 |
2008-12-02 |
Bristol-Myers Squibb Company |
Monocyclic heterocycles as kinase inhibitors
|
|
TW200538453A
(en)
|
2004-04-26 |
2005-12-01 |
Bristol Myers Squibb Co |
Bicyclic heterocycles as kinase inhibitors
|
|
US20090004277A1
(en)
*
|
2004-05-18 |
2009-01-01 |
Franchini Miriam K |
Nanoparticle dispersion containing lactam compound
|
|
US20050288290A1
(en)
|
2004-06-28 |
2005-12-29 |
Borzilleri Robert M |
Fused heterocyclic kinase inhibitors
|
|
US7432373B2
(en)
|
2004-06-28 |
2008-10-07 |
Bristol-Meyers Squibb Company |
Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
|
|
US7439246B2
(en)
|
2004-06-28 |
2008-10-21 |
Bristol-Myers Squibb Company |
Fused heterocyclic kinase inhibitors
|
|
WO2006017761A2
(en)
*
|
2004-08-05 |
2006-02-16 |
Emory University |
Epothilone analogues as therapeutic agents
|
|
EP1640004A1
(en)
*
|
2004-09-24 |
2006-03-29 |
Schering Aktiengesellschaft |
Use of epothilones in the treatment of bone metastases and bone tumors or cancers
|
|
US20060134214A1
(en)
*
|
2004-11-18 |
2006-06-22 |
Ismat Ullah |
Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
|
|
KR20070084325A
(ko)
*
|
2004-11-18 |
2007-08-24 |
브리스톨-마이어스 스큅 컴퍼니 |
익사베필론을 포함하는 장용성 코팅된 비드 및 그의 제조방법
|
|
US20060121511A1
(en)
|
2004-11-30 |
2006-06-08 |
Hyerim Lee |
Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
|
|
EP1674098A1
(en)
|
2004-12-23 |
2006-06-28 |
Schering Aktiengesellschaft |
Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
|
|
JP2008536479A
(ja)
|
2005-02-11 |
2008-09-11 |
ユニバーシティ オブ サザン カリフォルニア |
ジスルフィド架橋を有するタンパク質の発現法
|
|
CA2607940C
(en)
|
2005-05-18 |
2009-12-15 |
Aegera Therapeutics Inc. |
Bir domain binding compounds
|
|
US7348325B2
(en)
|
2005-11-30 |
2008-03-25 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
|
EP1994412A2
(en)
|
2006-03-31 |
2008-11-26 |
Brystol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
|
|
EP2029156A4
(en)
*
|
2006-05-01 |
2010-07-21 |
Univ Southern California |
COMBINATION THERAPY FOR CANCER TREATMENT
|
|
MY159563A
(en)
|
2006-05-16 |
2017-01-13 |
Pharmascience Inc |
Iap bir domain binding compounds
|
|
EP2089411A4
(en)
|
2006-12-04 |
2010-01-27 |
Univ Illinois |
COMPOSITIONS AND METHODS FOR CANCER TREATMENT WITH CUPREDOXINES AND CPG-RICH DNA
|
|
AU2008212788A1
(en)
|
2007-02-08 |
2008-08-14 |
The Board Of Trustees Of The University Of Illinois |
Compositions and methods to prevent cancer with cupredoxins
|
|
CN101754969A
(zh)
*
|
2007-05-25 |
2010-06-23 |
百时美施贵宝公司 |
制备埃坡霉素化合物和类似物的方法
|
|
US20090076099A1
(en)
*
|
2007-09-14 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched ixabepilone
|
|
EP2065054A1
(en)
|
2007-11-29 |
2009-06-03 |
Bayer Schering Pharma Aktiengesellschaft |
Combinations comprising a prostaglandin and uses thereof
|
|
EP2070521A1
(en)
|
2007-12-10 |
2009-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Surface-modified nanoparticles
|
|
DE102007059752A1
(de)
|
2007-12-10 |
2009-06-18 |
Bayer Schering Pharma Aktiengesellschaft |
Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
|
|
EP2227296B1
(en)
|
2008-01-08 |
2015-11-25 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
|
|
HRP20140783T1
(hr)
*
|
2008-04-24 |
2014-09-12 |
Bristol-Myers Squibb Company |
Uporaba epotilona d u lijeäśenju tau-povezanih bolesti ukljuäśujuä†i alzheimerovu bolest
|
|
US8802394B2
(en)
|
2008-11-13 |
2014-08-12 |
Radu O. Minea |
Method of expressing proteins with disulfide bridges with enhanced yields and activity
|
|
EP2210584A1
(en)
|
2009-01-27 |
2010-07-28 |
Bayer Schering Pharma Aktiengesellschaft |
Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
|
|
JP4500951B1
(ja)
*
|
2009-08-07 |
2010-07-14 |
学校法人神戸学院 |
Ｄｎａ合成酵素阻害剤
|
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
|
HRP20171537T1
(hr)
|
2009-11-05 |
2017-12-15 |
Rhizen Pharmaceuticals S.A. |
Novi modulatori benzopiran kinaze
|
|
NZ602368A
(en)
|
2010-02-12 |
2014-10-31 |
Pharmascience Inc |
Iap bir domain binding compounds
|
|
ES2715611T3
(es)
|
2010-05-17 |
2019-06-05 |
Incozen Therapeutics Pvt Ltd |
Compuestos novedosos de 3H-imidazo[4,5-b]piridina-3,5-disustituida y 3H-[1,2,3]triazolo[4,5-b]piridina 3,5-disustituida como moduladores de proteína cinasas
|
|
WO2011146638A1
(en)
|
2010-05-18 |
2011-11-24 |
Cerulean Pharma Inc. |
Compositions and methods for treatment of autoimmune and other diseases
|
|
JP2013527239A
(ja)
|
2010-06-01 |
2013-06-27 |
プラス・ケミカルス・エスアー |
イクサベピロンの固体形
|
|
CN101906099A
(zh)
*
|
2010-07-16 |
2010-12-08 |
泰州市今朝伟业精细化工有限公司 |
一种埃博霉素d-内酰胺衍生物化学合成方法
|
|
CN103442737B
(zh)
|
2011-01-20 |
2017-03-29 |
得克萨斯系统大学董事会 |
Mri标记、递送和提取系统及其制造方法和用途
|
|
US20140087309A1
(en)
*
|
2011-04-01 |
2014-03-27 |
The Research Foundation Of State University Of New York |
Olefin-triggered acid amplifiers
|
|
US20140193752A1
(en)
*
|
2011-04-01 |
2014-07-10 |
The Research Foundation Of State University Of New York |
Stabilized acid amplifiers
|
|
KR101992311B1
(ko)
|
2011-05-04 |
2019-09-27 |
리젠 파마슈티컬스 소시에떼 아노님 |
단백질 키나아제의 조절제로서 신규한 화합물
|
|
JP2014516075A
(ja)
|
2011-06-06 |
2014-07-07 |
シェブロン フィリップス ケミカル カンパニー エルピー |
癌治療のためのメタロセン化合物の使用
|
|
KR101972303B1
(ko)
|
2011-06-10 |
2019-04-25 |
메르사나 테라퓨틱스, 인코포레이티드 |
단백질-중합체-약물 접합체
|
|
CN102863474A
(zh)
|
2011-07-09 |
2013-01-09 |
陈小平 |
一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
|
|
WO2013008091A1
(en)
*
|
2011-07-13 |
2013-01-17 |
Xellia Pharmaceuticals Aps |
Manufacturing of epothilone derivatives and the use thereof
|
|
ES2458220T3
(es)
|
2011-09-12 |
2014-04-30 |
Agfa-Gevaert |
Métodos para el marcado por láser color de precursores de documento de seguridad
|
|
CN102993239A
(zh)
|
2011-09-19 |
2013-03-27 |
陈小平 |
离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
|
|
WO2013092998A1
(en)
|
2011-12-23 |
2013-06-27 |
Innate Pharma |
Enzymatic conjugation of antibodies
|
|
KR102164317B1
(ko)
|
2012-03-30 |
2020-10-13 |
리젠 파마슈티컬스 소시에떼 아노님 |
C-met 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3h-이미다조[4,5-b]피리딘 및 3,5- 디치환 -3h-[1,2,3]트리아졸로[4,5-b] 피리딘 화합물
|
|
WO2014009426A2
(en)
|
2012-07-13 |
2014-01-16 |
Innate Pharma |
Screening of conjugated antibodies
|
|
WO2014072482A1
(en)
|
2012-11-09 |
2014-05-15 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
|
WO2014075391A1
(zh)
|
2012-11-17 |
2014-05-22 |
北京市丰硕维康技术开发有限责任公司 |
离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
|
|
US9353150B2
(en)
|
2012-12-04 |
2016-05-31 |
Massachusetts Institute Of Technology |
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
|
|
EP2928504B1
(en)
|
2012-12-10 |
2019-02-20 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
US9872918B2
(en)
|
2012-12-12 |
2018-01-23 |
Mersana Therapeutics, Inc. |
Hydroxyl-polymer-drug-protein conjugates
|
|
US9309259B2
(en)
*
|
2013-03-08 |
2016-04-12 |
Scinopharm Taiwan, Ltd. |
Process for ixabepilone, and intermediates thereof
|
|
WO2014140300A1
(en)
|
2013-03-15 |
2014-09-18 |
Innate Pharma |
Solid phase tgase-mediated conjugation of antibodies
|
|
CA2905509A1
(en)
|
2013-03-15 |
2014-09-18 |
Memorial Sloan-Kettering Cancer Center |
Hsp90-targeted cardiac imaging and therapy
|
|
EA201600003A1
(ru)
|
2013-06-11 |
2016-06-30 |
Байер Фарма Акциенгезельшафт |
КОМБИНАЦИИ ДЛЯ ЛЕЧЕНИЯ РАКА, СОДЕРЖАЩИЕ ИНГИБИТОР Mps-1 КИНАЗЫ И ИНГИБИТОР МИТОЗА
|
|
WO2014202773A1
(en)
|
2013-06-20 |
2014-12-24 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
KR20160042871A
(ko)
|
2013-06-21 |
2016-04-20 |
이나뜨 파르마, 에스.아. |
폴리펩티드의 효소적 콘쥬게이션
|
|
ES2726850T3
(es)
|
2013-10-11 |
2019-10-09 |
Mersana Therapeutics Inc |
Conjugados de proteína-polímero-fármaco
|
|
PL3054992T3
(pl)
|
2013-10-11 |
2020-01-31 |
Asana Biosciences, Llc |
Koniugaty białko-polimer-lek
|
|
US10341459B2
(en)
|
2015-09-18 |
2019-07-02 |
International Business Machines Corporation |
Personalized content and services based on profile information
|
|
WO2017197045A1
(en)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Convergent and enantioselective total synthesis of communesin analogs
|
|
US11617799B2
(en)
|
2016-06-27 |
2023-04-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
WO2018209239A1
(en)
|
2017-05-11 |
2018-11-15 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
|
WO2018237262A1
(en)
|
2017-06-22 |
2018-12-27 |
Mersana Therapeutics, Inc. |
Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
WO2019092148A1
(en)
|
2017-11-10 |
2019-05-16 |
Innate Pharma |
Antibodies with functionalized glutamine residues
|
|
EP3787691A1
(en)
|
2018-05-04 |
2021-03-10 |
Tagworks Pharmaceuticals B.V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
|
EP4382167A3
(en)
|
2018-05-04 |
2024-08-28 |
Tagworks Pharmaceuticals B.V. |
Compounds comprising a linker for increasing transcyclooctene stability
|
|
AU2019369340A1
(en)
|
2018-10-29 |
2021-05-20 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
|
US11535634B2
(en)
|
2019-06-05 |
2022-12-27 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
|
EP4382129A3
(en)
|
2019-06-17 |
2024-07-03 |
Tagworks Pharmaceuticals B.V. |
Compounds for fast and efficient click release
|
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
|
WO2021142202A1
(en)
|
2020-01-10 |
2021-07-15 |
R-Pharm Us Operating Llc |
Compositions of ixabepilone
|
|
WO2022182415A1
(en)
|
2021-02-24 |
2022-09-01 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
|
JP2024532537A
(ja)
|
2021-09-06 |
2024-09-05 |
ヴェラクサ バイオテック ゲーエムベーハー |
真核生物における遺伝暗号の拡張のための新規アミノアシルｔＲＮＡ合成酵素変異体
|
|
CA3238627A1
(en)
|
2021-11-25 |
2023-06-01 |
Christine Kohler |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
|
EP4186529B1
(en)
|
2021-11-25 |
2025-07-09 |
Veraxa Biotech GmbH |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
|
AU2022404647A1
(en)
|
2021-12-08 |
2024-06-13 |
European Molecular Biology Laboratory |
Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
|
|
CA3244098A1
(en)
|
2022-02-15 |
2023-08-24 |
Tagworks Pharmaceuticals B V |
Masked il12 protein
|
|
KR20250049569A
(ko)
|
2022-07-15 |
2025-04-11 |
페온 테라퓨틱스 리미티드 |
항체-약물 접합체
|
|
EP4602023A1
(en)
|
2022-10-12 |
2025-08-20 |
Tagworks Pharmaceuticals B.V. |
Strained bicyclononenes
|
|
CN120569216A
(zh)
|
2023-01-20 |
2025-08-29 |
巴斯夫欧洲公司 |
稳定型生物聚合物组合物、其制造和用途
|
|
CN121100004A
(zh)
|
2023-03-10 |
2025-12-09 |
泰克沃尔科斯制药有限公司 |
具有改进的t-连接子的反式-环辛烯
|
|
WO2025021929A1
(en)
|
2023-07-27 |
2025-01-30 |
Veraxa Biotech Gmbh |
Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same
|
|
WO2025056807A1
(en)
|
2023-09-15 |
2025-03-20 |
Basf Se |
Stabilized biopolymer composition, their manufacture and use
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
WO2025174248A1
(en)
|
2024-02-16 |
2025-08-21 |
Tagworks Pharmaceuticals B.V. |
Trans-cyclooctenes with "or gate" release
|